Pfizer, ChemRar sign MoU to explore drug research, development in Russia
The two companies intend to develop certain compounds through technology transfer and out-licensing deals with venture funding from Pfizer’s pipeline. Under the terms of the MoU, the two
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.